HARMONY BIOSCIENCES HOLDINGS, INC. Retained Earnings
HARMONY BIOSCIENCES HOLDINGS, INC. (HRMY) had Retained Earnings of $268.82 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-04
- 2026-06-30: Retained Earnings (Accumulated Deficit) $268.82M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) $193.39M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) $160.90M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) $138.42M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | $268.82M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $193.39M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $160.90M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $138.42M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $87.55M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $47.78M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $2.22M 10-K · filed 2026-02-24 |
| 2024-09-30 | -$47.26M 10-Q · filed 2024-10-29 |
| 2024-06-30 | -$93.35M 10-Q · filed 2024-08-06 |
| 2024-03-31 | -$104.94M 10-Q · filed 2024-04-30 |
| 2023-12-31 | -$143.28M 10-K · filed 2025-02-25 |
| 2023-09-30 | -$169.88M 10-Q · filed 2023-10-31 |
| 2023-06-30 | -$208.34M 10-Q · filed 2023-08-01 |
| 2023-03-31 | -$242.65M 10-Q · filed 2023-05-02 |
| 2022-12-31 | -$272.13M 10-K · filed 2024-02-22 |
| 2022-09-30 | -$320.64M 10-Q · filed 2022-11-01 |
| 2022-06-30 | -$408.58M 10-Q · filed 2022-08-02 |
| 2022-03-31 | -$432.11M 10-Q · filed 2022-05-03 |
| 2021-12-31 | -$453.60M 10-K · filed 2023-02-21 |
| 2021-09-30 | -$476.31M 10-Q · filed 2021-11-09 |
| 2021-06-30 | -$466.69M 10-Q · filed 2021-08-10 |
| 2021-03-31 | -$480.81M 10-Q · filed 2021-05-11 |
| 2020-12-31 | -$488.19M 10-K · filed 2022-02-28 |
| 2020-09-30 | -$487.99M 10-Q · filed 2020-11-12 |
| 2019-12-31 | -$422.86M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |